Abstract 6417: LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML)Vivian Salama, Marina Konopleva, P.L. Milligan et al.|Cancer Research|2020Cited by 8
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical ModelsNathan A. Brooks, Raymond Gilmour, Anna Skwarska et al.|Blood Cancer Discovery|2026Cited by 0